Your browser doesn't support javascript.
Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.
He, Jun; Hu, Lijun; Huang, Xiaojun; Wang, Chenran; Zhang, Zhimin; Wang, Ying; Zhang, Dongmei; Ye, Wencai.
  • He J; Institute of Traditional Chinese Medicine & Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, People's Republic of China; Institute of Laboratory Animal Science, Jinan University, Guangzhou 510632, China.
  • Hu L; Institute of Traditional Chinese Medicine & Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, People's Republic of China; Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, College of Pharmacy, Jinan
  • Huang X; Institute of Traditional Chinese Medicine & Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, People's Republic of China; Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, College of Pharmacy, Jinan
  • Wang C; Institute of Traditional Chinese Medicine & Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, People's Republic of China; Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, College of Pharmacy, Jinan
  • Zhang Z; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), College of Pharmacy, Jinan University, Guangzhou, China.
  • Wang Y; Institute of Traditional Chinese Medicine & Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, People's Republic of China; Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, College of Pharmacy, Jinan
  • Zhang D; Institute of Traditional Chinese Medicine & Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, People's Republic of China; Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, College of Pharmacy, Jinan
  • Ye W; Institute of Traditional Chinese Medicine & Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, People's Republic of China; Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, College of Pharmacy, Jinan
Int J Antimicrob Agents ; 56(2): 106055, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-593424
Semantic information from SemMedBD (by NLM)
1. SARS coronavirus CAUSES Acute respiratory disease
Subject
SARS coronavirus
Predicate
CAUSES
Object
Acute respiratory disease
2. Middle East Respiratory Syndrome Coronavirus CAUSES Acute respiratory disease
Subject
Middle East Respiratory Syndrome Coronavirus
Predicate
CAUSES
Object
Acute respiratory disease
3. 2019 novel coronavirus CAUSES Disease
Subject
2019 novel coronavirus
Predicate
CAUSES
Object
Disease
4. Genus: Coronavirus CAUSES Disease
Subject
Genus: Coronavirus
Predicate
CAUSES
Object
Disease
5. Polyproteins AFFECTS Disease
Subject
Polyproteins
Predicate
AFFECTS
Object
Disease
6. Protease Inhibitors TREATS COVID-19
Subject
Protease Inhibitors
Predicate
TREATS
Object
COVID-19
7. SARS coronavirus CAUSES Acute respiratory disease
Subject
SARS coronavirus
Predicate
CAUSES
Object
Acute respiratory disease
8. Middle East Respiratory Syndrome Coronavirus CAUSES Acute respiratory disease
Subject
Middle East Respiratory Syndrome Coronavirus
Predicate
CAUSES
Object
Acute respiratory disease
9. 2019 novel coronavirus CAUSES Disease
Subject
2019 novel coronavirus
Predicate
CAUSES
Object
Disease
10. Genus: Coronavirus CAUSES Disease
Subject
Genus: Coronavirus
Predicate
CAUSES
Object
Disease
11. Polyproteins AFFECTS Disease
Subject
Polyproteins
Predicate
AFFECTS
Object
Disease
12. Protease Inhibitors TREATS COVID-19
Subject
Protease Inhibitors
Predicate
TREATS
Object
COVID-19
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), which belong to the same Betacoronavirus genus, induces severe acute respiratory disease that is a threat to human health. Since the outbreak of infection by SARS-CoV-2 began, which causes coronavirus disease 2019 (COVID-19), the disease has rapidly spread worldwide. Thus, a search for effective drugs able to inhibit SARS-CoV-2 has become a global pursuit. The 3C-like protease (3CLpro), which hydrolyses viral polyproteins to produce functional proteins, is essential for coronavirus replication and is considered an important therapeutic target for diseases caused by coronaviruses, including COVID-19. Many 3CLpro inhibitors have been proposed and some new drug candidates have achieved success in preclinical studies. In this review, we briefly describe recent developments in determining the structure of 3CLpro and its function in coronavirus replication and summarise new insights into 3CLpro inhibitors and their mechanisms of action. The clinical application prospects and limitations of 3CLpro inhibitors for COVID-19 treatment are also discussed.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Protease Inhibitors / Viral Nonstructural Proteins / Coronavirus Infections Type of study: Prognostic study Limits: Humans Language: English Journal: Int J Antimicrob Agents Year: 2020 Document Type: Article Affiliation country: J.ijantimicag.2020.106055

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Protease Inhibitors / Viral Nonstructural Proteins / Coronavirus Infections Type of study: Prognostic study Limits: Humans Language: English Journal: Int J Antimicrob Agents Year: 2020 Document Type: Article Affiliation country: J.ijantimicag.2020.106055